Tirzepatide vs semaglutide

Arranging your appointment

Tirzepatide activates GIP and GLP-1 receptors. Semaglutide activates GLP-1 receptors. Trials use specified populations, doses, and durations. Comparing percentages from unrelated trials can be misleading.

Tirzepatide and semaglutide comparison

Tirzepatide and semaglutide are different treatments, and their brands have different indications. A useful comparison considers your diagnosis, treatment response, side effects, administration, and ability to continue care. A larger average trial result does not make one medicine right for everyone.

Eligibility: Tirzepatide and semaglutide comparison

Both have adult obesity-treatment options under the appropriate brand and criteria. Diabetes, pediatric, cardiovascular, OSA, and MASH indications differ. Review the exact label instead of transferring an indication between brands.

What to expect: Tirzepatide and semaglutide comparison

Review what you have already taken, dose and duration, side effects, nutrition, glucose when relevant, and access. A plateau needs assessment before switching. The prescriber sets a transition and titration plan. Do not overlap treatments or convert milligrams yourself.

Preparing for your appointment

Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.

Risks and when to seek help

Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs an emergency department assessment now. Call 911 for severe breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Do not wait for a nutrition visit. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Tirzepatide has oral-contraceptive precautions after starting and increasing. Semaglutide has a two-month planned-pregnancy interval for weight treatment. These details can change the choice.

Follow-up and treatment review

Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.

Appointments, costs and coverage

Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.

Medical sources

• mounjaro current US prescribing information
• zepbound current US prescribing information
• wegovy current US prescribing information
• ozempic-injection current US prescribing information
• NIDDK prescription weight-management medicines
• SURMOUNT-5 primary trial abstract
• When to use the emergency room - adult: MedlinePlus Medical Encyclopedia
• FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products | FDA
• FDA unapproved GLP-1 drugs, salt forms and compounding concerns